Zanzalintinib
Small molecule
Also known as XL092
Evidence outlook · regulatory review
Colorectal Cancer: application under FDA review, decision date 2026-12-03
FDA accepts zanzalintinib NDA (2026-02-02). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Latest reported trial: STELLAR-303 (NCT05425940) · Phase 3 · met primary endpoint · grade pending
Also in development:Non-Small Cell Lung Cancer · Phase 2Clear Cell Renal Cell Carcinoma · Phase 2Renal Cell Carcinoma · Phase 3
Company guidance: topline data expected Second Half of 2026 (NCT05678673; Exelixis, 5 Aug 2026). “Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STELLAR-001 NCT03845166 · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer Registry: NCT03845166 | 1 | Dose-Escalation Stage: MTD/recommended dose for XL092 (Up to 24 months); Cohort-Expansion Stage: Objective Response Rate (ORR) (Up to 24 months); Cohort-Expansion Stage (except Cohort H): Progression-Free Survival (PFS) (Up to 24 months); Cohort-Expansion Stage (Cohort H only): Overall Survival (OS) (Up to 24 months) 2026-08-31 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
STELLAR-303 NCT05425940 · Colorectal Cancer Registry: NCT05425940 | 3 | Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants (Up to 32 months); Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants (Up to 32 months) 2026-06-16 | Overall survival (ITT): stratified HR 0.80 (95% CI 0.69-0.93; p=0.0045), median 10.9 vs 9.4 months, zanzalintinib + atezolizumab vs regorafenib (STELLAR-303, Lancet 2025). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Clear Cell Renal Cell Carcinoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zanzalintinib: this drug | Phase 2 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Casdatifan | Phase 3 | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Darlifarnib | Phase 1 | Small molecule | Farnesyltransferase | not yet graded | No reviewed efficacy summary in this indication | |
| HS-IT101 | Phase 1 | Cell therapy | Autologous tumor neoantigens (polyclonal, patient-specific) | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb819 | Phase 1 | Multispecific antibody | ENPP3 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CTX131 | Discontinued | Cell therapy | CD70 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(44 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zanzalintinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
Company guidance: topline data expected Second Half of 2026 (Exelixis, 5 Aug 2026). “Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026.” Source ↗
What to watch
What to watch
2027 (5)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (19)
February 2028 (2)
March 2028 (2)
May 2028 (1)
What to watch
June 2028 (3)
What to watch
What to watch
What to watch
July 2028 (4)
What to watch
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (2)
What to watch
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (7)
March 2029 (1)
What to watch
April 2029 (2)
May 2029 (1)
What to watch
June 2029 (1)
What to watch
October 2029 (1)
What to watch
November 2029 (1)
What to watch
2030 (5)
March 2030 (1)
What to watch
April 2030 (1)
What to watch
May 2030 (1)
What to watch
September 2030 (1)
What to watch
November 2030 (1)
What to watch
2031 (3)
January 2031 (1)
What to watch
May 2031 (1)
What to watch
October 2031 (1)
What to watch
2032 (1)
February 2032 (1)
What to watch
2034 (1)
December 2034 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent